DRG Market Assessment reports

Hormonal therapy remains the foundation of drug treatment for prostate cancer across all patient populations, with ADT serving as the universal backbone. ARPIs—enzalutamide, apalutamide, and…

Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Second-generation hormone therapies have expanded beyond metastatic castrate-…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…

Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Second-generation hormone therapies have expanded beyond metastatic castrate-…

Clarivate Epidemiology’s coverage of prostate cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of prostate cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and diagnosed…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts of key prostate cancer patient populations, covering 171 countries and more…

Clarivate Epidemiology’s coverage of prostate cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Prostate cancer is the second-most-prevalent cancer in men, significantly impacting male mortality rates. Hormonal therapy is a cornerstone of drug treatment for all stages of prostate cancer…

Hormonal agents are routinely used in all lines of therapy and thus dominate the treatment of prostate cancer. Next-generation hormonal treatments have expanded beyond metastatic castrate-resistant…

The treatment of prostate cancer in China is undergoing a transformative phase, characterized by an increase in diagnosed incident cases due to improved screening techniques. This shift is…

The treatment of prostate cancer in China is undergoing a transformative phase, characterized by an increase in diagnosed incident cases due to improved screening techniques. This shift is…